TGTX - TG Therapeutics, Inc.
7.42 0.00 (0.00%)
After hours: 5:22PM EDT
| Previous Close | 7.41 |
| Open | 7.54 |
| Bid | 7.36 x 800 |
| Ask | 7.44 x 1100 |
| Day's Range | 7.06 - 7.56 |
| 52 Week Range | 3.32 - 16.27 |
| Volume | 2,793,034 |
| Avg. Volume | 2,035,511 |
| Market Cap | 607.512M |
| Beta (3Y Monthly) | 1.50 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.30 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.50 |
- GlobeNewswire•8 days ago
TG Therapeutics, Inc. Announces Data Presentation at the Upcoming American Academy of Neurology 71st Annual Meeting
TG Therapeutics, Inc. (TGTX), today announced that data from the Phase 2 multicenter trial evaluating ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of Multiple Sclerosis (RMS) has been selected for presentation at the upcoming American Academy of Neurology (AAN) annual meeting, to be held May 4 – 10, 2019 in Philadelphia, Pennsylvania. Final data from the core Phase 2 trial has been previously presented, most recently at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual meeting in Dallas, TX. In addition to highlighting the final Phase 2 data, the AAN presentation plans to include data from the open label extension (OLE), a trial made available to any patient who completed the core Phase 2 trial allowing them to continue treatment with ublituximab.
- Zacks•9 days ago
What Makes TG Therapeutics (TGTX) a New Strong Buy Stock
TG Therapeutics (TGTX) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- GlobeNewswire•9 days ago
TG Therapeutics to Present at the Cowen 39th Annual Health Care Conference
NEW YORK, March 11, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will.
- GlobeNewswire•12 days ago
TG Therapeutics Announces Positive Data Safety Monitoring Board Reviews of UNITY-CLL and UNITY-NHL Clinical Trials
TG Therapeutics, Inc. (TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated cancers and autoimmune diseases, today announced the successful outcome of meetings held by the independent Data Safety Monitoring Boards (DSMBs) for both the UNITY-CLL trial and for the UNITY-NHL trial. Michael S. Weiss, Executive Chairman and Chief Executive Officer of TG Therapeutics stated, "We are highly encouraged that based on the progression-free survival data accumulated to date, the UNITY-CLL DSMB determined that the study was not futile and supported continuation of the trial as planned.
- Simply Wall St.•13 days ago
Those Who Purchased TG Therapeutics Shares A Year Ago Have A 57% Loss To Show For It
This month, we saw the TG Therapeutics, Inc. (NASDAQ:TGTX) up an impressive 62%. But that doesn't change the fact that the returns over the last year have been disappointing. Specifically,Read More...
- Motley Fool•16 days ago
This Is Why TG Therapeutics Stock Soared 65.9% in February
A string of positive news on drugs in development sparked investor excitement.
- Zacks•18 days ago
The Meet Group (MEET) to Report Q4 Earnings: What's in Store?
The Meet Group's (MEET) fourth-quarter 2018 results are expected to benefit from strong growth in video revenues.
- GlobeNewswire•19 days ago
TG Therapeutics Announces Approximately $85 million in Equity and Debt Financings
TG Therapeutics, Inc. (TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases, today announced approximately $85 million in equity and debt financing. The Company priced a public offering of its common stock for gross proceeds of approximately $25.2 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company. In addition, the Company granted the underwriters a 30-day option to purchase $3.8 million of additional shares of common stock.
- Benzinga•19 days ago
The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 28) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Abbott ...
- TheStreet.com•19 days ago
3 Recent Big Gainers Kick Off the Dramatic Return of 'Small-Cap Friday'
This is a nice win for this razor and razor-blade concern and helped drive a 15% rally in T2 Biosystems on Thursday. This trial combined the use of TG Therapeutics' compounds TG-1101 and TGR-1202 and Imbruvica to treat chronic lymphocytic leukemia or small lymphocytic lymphoma. After the bell Thursday, TG Therapeutics took advantage of the rally in the stock to initiate a raise of capital.
- Zacks•19 days ago
Why These Pharma ETFs Rallied on Thursday
A few pharma ETFs hit a one-month high on Feb 28. Why?
- GlobeNewswire•19 days ago
TG Therapeutics, Inc. Announces Final Phase 2 Multiple Sclerosis Data Presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Annual Meeting
TG Therapeutics, Inc. (TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases, today announced the final results from the Phase 2 multicenter trial of ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of Multiple Sclerosis (RMS). The data were presented yesterday at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual meeting held in Dallas, TX. The data was previously presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting held in October of 2018.
- Motley Fool•19 days ago
Why TG Therapeutics Stock Skyrocketed 30.5% Today
Positive data from a cohort in a key trial ignited investor optimism.
- GlobeNewswire•19 days ago
TG Therapeutics Announces Proposed Public Offering of Common Stock and Closing of $60.0 Million Venture Debt Financing
TG Therapeutics, Inc. (TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. TG Therapeutics intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. Cantor Fitzgerald & Co. is acting as sole book-running manager for the offering.
- GlobeNewswire•20 days ago
TG Therapeutics Announces Positive Outcome from UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib in Patients with Relapsed/Refractory Marginal Zone Lymphoma
Study met the primary endpoint of Overall Response Rate (ORR) Interim data to be presented in an oral presentation at the 2019 American Association of Cancer Research (AACR).
- Zacks•22 days ago
Will R&D Focus Fuel DENTSPLY SIRONA's (XRAY) Earnings in Q4?
DENTSPLY SIRONA's (XRAY) overall growth strategy depends on product innovation and R&D focus, which is likely to drive the top line in Q4.
- GlobeNewswire•22 days ago
TG Therapeutics Announces Initiation of Phase I First-in-Human Clinical Trial of its Anti-CD47/CD19 Bispecific Antibody, TG-1801, in Patients with Relapsed or Refractory B-cell Lymphoma
TG Therapeutics, Inc. (TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases, today announced the commencement of a Phase I first-in-human trial of TG-1801, the Company’s novel first-in-class anti-CD47/CD19 bispecific antibody, in patients with relapsed or refractory B-cell lymphoma. TG-1801 is the first therapy to target both CD19, a B-cell specific marker widely expressed across B-cell malignancies, and CD47, the “don’t eat me” signal used by both healthy and tumor cells to evade macrophage mediated phagocytosis. CD47 is expressed ubiquitously on normal cells, including red blood cells and platelets.
- GlobeNewswire•26 days ago
TG Therapeutics, Inc. Announces Data Presentation at the Upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Annual Meeting
TG Therapeutics, Inc. (TGTX), today announced that the final Phase 2 data from the multicenter trial of ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of Multiple Sclerosis (RMS) has been selected for presentation at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual meeting, to be held February 28 through March 2, 2019 in Dallas, Texas. This data was previously presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting held in October of 2018. Highlights from the abstract and details of the poster presentation are outlined below.
- Zacks•28 days ago
Key Factors to Know Ahead of TransEnterix (TRXC) Q4 Earnings
TransEnterix (TRXC) is anticipated to witness robust top-line growth in Q4 on the back of multiple product developments.
- Zacks•last month
HMS Holdings (HMSY) to Report Q4 Earnings: What's in Store?
HMS Holdings (HMSY) expects to gain from its total population management or TPM business in fourth-quarter 2018.
- Zacks•last month
Key Factors Likely to Shape CVS Health's (CVS) Q4 Earnings
CVS Health (CVS) expects drug price inflation, product launches and higher utilization to fuel growth in Q4.
- Zacks•last month
Can M&A Activity Drive Quest Diagnostics (DGX) Q4 Earnings?
Quest Diagnostics' (DGX) increasing partnerships with other health care leaders and strategic acquisitions are promising abundant opportunities for the company's top and bottom-line improvement.
- Zacks•2 months ago
TG Therapeutics (TGTX) Upgraded to Buy: Here's What You Should Know
TG Therapeutics (TGTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- GlobeNewswire•2 months ago
TG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase I Triple Therapy Combination Trial of Ublituximab, Umbralisib, and Ibrutinib in The Lancet Haematology
TG Therapeutics, Inc. (TGTX) today announced the publication of results from the multicenter Phase 1 triple combination trial of ublituximab (TG-1101), the Company’s anti-CD20 monoclonal antibody, umbralisib (TGR-1202), the Company’s oral once-daily PI3K delta inhibitor, and ibrutinib, the oral Bruton's tyrosine kinase (BTK) inhibitor, in The Lancet Haematology. The paper includes safety and efficacy information from patients with relapsed or refractory B-cell malignancies, including 23 patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and 23 patients with non-Hodgkin lymphoma (NHL).
- Zacks•2 months ago
Has TG Therapeutics (TGTX) Outpaced Other Medical Stocks This Year?
Is (TGTX) Outperforming Other Medical Stocks This Year?
